“知名牛散”郭伟松增持童药龙头华特达因股份至5%，此前已跻身公司第二大股东

Core Viewpoint - The significant increase in shareholding by investor Guo Weisong in Shandong Huate Dain Health Co., Ltd. indicates confidence in the company's value and future prospects, as he aims to establish a long-term investment relationship without seeking control over the company [1][2]. Group 1: Shareholding Changes - Guo Weisong increased his shareholding to 5% by purchasing 24,400 shares at an average price of 29.19 yuan per share, totaling approximately 712,200 yuan [1][2]. - Following this transaction, Guo Weisong's total shareholding reached 11,716,624 shares, representing 5% of the company's total equity [1][2]. - Prior to this increase, Guo Weisong held 11,692,224 shares, which accounted for 4.99% of the total equity [2]. Group 2: Company Overview - Shandong Huate Dain specializes in the pharmaceutical industry, focusing on children's health products, with key offerings including Yikexin, YDxin, and various pediatric medications [3]. - The company reported a revenue of 616 million yuan in the first quarter of 2025, reflecting a year-on-year growth of 7.78%, while the net profit attributable to shareholders was 182 million yuan, up 8.13% year-on-year [3].